Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

1.1K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.1K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.2K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.2K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

3.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
3.3K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

722
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
722
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

491
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
491
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Optimal serum potassium concentrations in heart failure: an individual patient data meta-analysis.

European heart journal·2026
Same author

Vagal Nerve Stimulation in Patients With Heart Failure and Reduced Ejection Fraction: The ANTHEM-HFrEF Trial.

Journal of the American College of Cardiology·2026
Same author

iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025.

Heart views : the official journal of the Gulf Heart Association·2026
Same author

Comparative Prognosis of Chagas and Other Cardiomyopathies.

Journal of the American College of Cardiology·2026
Same author

Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure: A Prespecified Analysis From EMPULSE.

JACC. Heart failure·2026
Same author

Mitral regurgitation in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF.

European journal of heart failure·2026
Same journal

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Lancet (London, England)·2026
Same journal

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Lancet (London, England)·2026
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
查看所有相关文章

相关实验视频

Updated: Mar 3, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

心脏衰竭

Marco Metra1, John R Teerlink2

  • 1Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.

Lancet (London, England)
|May 3, 2017
PubMed
概括
此摘要是机器生成的。

心力衰竭的治疗正在得到改善,新的药物如血管激素受体尼普利辛抑制剂 (RNAI) 显得有前途. 然而,心力衰竭的有效治疗方法仍然难以捉摸,这凸显了未满足的临床需求.

更多相关视频

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K

相关实验视频

Last Updated: Mar 3, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K

科学领域:

  • 心脏病学
  • 内部医学

背景情况:

  • 由于人口老龄化和急性心血管事件管理的改善,心力衰竭 (HF) 是一个全球性的健康问题.
  • 虽然存在心力衰竭降低射出分数 (HFrEF) 的治疗方法,如ACE抑制剂,ARB,β- 阻断剂和RNAI,但仍有大量未满足的需求,特别是心力衰竭保留射出分数 (HFpEF).

研究的目的:

  • 审查目前心力衰竭的治疗策略,重点关注进展和剩余的挑战.
  • 突显RNAI和左心室辅助器件 (LVAD) 等疗法的不断变化的作用.
  • 讨论HFpEF有限的治疗选择以及需要新的治疗方法.

主要方法:

  • 对心力衰竭流行病学,病理生理学和治疗疗效的当前文献的综述.
  • 对药物和基于设备的治疗指南的分析.
  • 对HFrEF和HFpEF新药机制的正在进行的研究进行审查.

主要成果:

  • 与埃纳拉普利尔相比,血管素受体抑制剂 (RNAI) 的治疗结果有所改善,因此建议在HFrEF中使用它们.
  • 由于安全性提高,左心室辅助器件 (LVAD) 越来越多地用于严重的HF.
  • 尽管有一些关于螺旋的证据,但对于HFpEF没有明确的治疗方法.

结论:

  • 虽然HFrEF治疗的进展,包括RNA和LVAD,正在改善患者的治疗结果,但HFpEF仍然是一个治疗挑战.
  • 包括心肌激活剂在内的新药开发对于解决HFrEF和HFpEF未满足的需求至关重要.
  • 为了为日益增长的心力衰竭患者开发有效的治疗方法,